Will Bristol-Myers Squibb stock avoid deeper losses amid ongoing seller pressure?

Traders Union
All News
Stocks
Bristol-Myers Squibb drops 3.09% today

Highlights

Bristol-Myers Squibb reported positive topline results from two Phase 3 trials for admilparant and RYZ101, advancing late-stage development.
Admilparant achieved its primary endpoint in the Phase 3 ALOFT-IPF trial for idiopathic pulmonary fibrosis, strengthening future regulatory potential.
Shares of Bristol-Myers Squibb remain under sustained selling pressure with bearish momentum signals and an expected range of $56.65 to $57.93.

Late-stage trial successes lift R&D outlook despite selling pressure

Bristol-Myers Squibb announced positive topline results from two Phase 3 clinical trials for its investigational drugs admilparant and RYZ101, demonstrating progress in its late-stage pipeline, according to Gurufocus. The company also reported that its Phase 3 ALOFT-IPF trial for admilparant in adults with idiopathic pulmonary fibrosis successfully met its primary endpoint, as noted by Stockhouse. These confirmed data points enhance the company's future regulatory prospects and add credibility to its R&D pipeline, though price action has remained under broader selling pressure.

Oversold signals deepen as sellers dominate below technical barriers

BMY is currently trading below the MA-20 ($59.35) and MA-50 ($59.81) on the hourly chart and under the MA-200 ($59.53) on the daily timeframe. The Ichimoku Kijun sits at $58.74 and currently acts as immediate resistance. Momentum indicators remain in negative territory: MACD and ADX both indicate a sell bias, while RSI at 27.46, as well as Stochastic RSI and CCI, all show oversold conditions. Bull/Bear Power points to strong seller dominance, and the Awesome Oscillator confirms a prevailing downtrend. The recent session saw BMY closing near the day's low amid high volatility, with no divergence across technical signals.

Sideways trading expected as upside remains constrained by resistance

Over the next several sessions, BMY is likely to continue trading in a range between $56.65 and $57.93, with a very low probability of any near-term upward movement. The baseline scenario is for sideways trading within this typical volatility band relative to current levels. Upside attempts would require a break above the $58.74 resistance area, while a sustained drop below the $56.65 support would open the path for further declines.

Anton Kharitonov, expert at Traders Union, views BMY’s technical setup as weak despite encouraging late-stage trial results. He points out that the stock remains oversold with sellers clearly dominating, and prices are stuck below all key moving averages. He cautions that sentiment is not improving yet, and the risk of further declines persists if $56.65 fails. "Until we see a break above $58.74 or a clear technical reversal, I remain defensive and do not see any reason to enter long positions here."

Earlier, analysts noted that Bristol-Myers Squibb was experiencing sustained downside momentum despite ongoing corporate initiatives and industry engagement. The latest clinical trial successes add a positive dimension to the company's prospects, but with price action anchored below major moving averages and a muted technical outlook, traders should monitor $56.65 as the next critical support level for potential downside risk.

Source of Data: BMY Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.